Plasma Fractionation Market Size, Share & COVID-19 Impact Analysis, By Product (Immunoglobulin, Albumin, Coagulation Factors, Protease Inhibitors, and Others), By Application (Immunology & Neurology, Hematology, Critical Care, Pulmonology, and Others), By End-user (Hospitals & Clinics, Clinical Research Laboratories, and Others), and Regional Forecast, 2020-2027

The global plasma fractionation market size was USD 25.44 billion in 2019 and is projected to reach USD 48.55 billion by 2027, exhibiting a CAGR of 7.6% during the forecast period.

Plasma fractionation has always ignited curiosity among researchers and industrialists alike. The therapeutic efficacies of blood plasma to treat and manage immunodeficiency diseases have helped the growth of the market. Cryo precipitation and ethanol fractionation are the major processes that are carried out to separate therapeutic protein components from whole blood. Protein components such as prothrombin complex, thrombin, fibrinogen among others play a major role in the management of diseases. These plasma fractionation products have therapeutic efficiencies to treat diseases such as congenital metabolic deficiencies, trauma, immunological disorders, and other life-threatening diseases.

Use of Plasma Therapy in COVID-19

The outbreak of COVID-19 has urged scientists to experiment with plasma therapy on affected people. As of August 2020, around 5 million people have been tested positive for the disease in the U.S alone since the outbreak.  The patients are administered blood plasma in the recovery as there are no specific treatment medicine or vaccine against the disease. Hence, the promising results shown by plasma therapy in disease management and recovery will spur opportunities for the market amid the global pandemic.

LATEST TRENDS

Request a Free sample to learn more about this report.

Shift Towards Advanced Treatment Options to Boost Market Scope

The rising demand for plasma products globally has enabled manufacturers to dedicate manufacturing units for the production of plasma proteins. This was significantly witnessed in countries like China. China is among the largest producers and consumers of plasma-derived products. According to the journal Annals of Blood, nearly 7 Mn liters of plasma is collected in China per year. According to the data published in the research paper of the National Institute of Health 40,000 kg of intravenous immunoglobulin and 500,000 kg of human albumin are produced each year worldwide.

DRIVING FACTORS

Increasing Adoption of Immunoglobulin to Bolster Market Growth

One of the most predominant and crucial factors for the growth of the market is the increasing adoption of immunoglobulin for the management, treatment, and diagnosis of metabolic diseases worldwide. Thus, the high utilization of immunoglobulin will magnify its dominance and improve market prospects. Immunoglobulin is glycoprotein molecules that are derived through plasma and act as antibodies. There has been constant research and development to cognize the efficacy and therapeutic nature of immunoglobulin to treat complex diseases such as Alzheimer’s and other autoimmune disorders. These factors cumulatively are anticipated to drive the market growth.

Establishment of GLP Compliant Facilities to Produce Plasma Products to Augment Market Growth

The growing focus on establishing advanced plasma fractionation facilities by key market players. For instance, in February 2019, Kedrion Biopharma announced that the company received FDA approval for establishing a plasma manufacturing facility in Melville that would be dedicated to producing plasma proteins. The establishment of such facilities is of utmost importance to carry out the fractionation process in a sterile microorganism free environment. Additionally, in light of the 2019-2020 global pandemic, such facilities will play a crucial role in maintaining the supply-demand cycle of fractionation proteins worldwide. This has, in turn, accelerated the growth of the market

RESTRAINING FACTORS

Stringent Regulatory Policies to Restrain Market Growth

As plasma products are derived from whole blood, the product is stringently regulated by regulatory bodies. Stringent regulations pertaining to the manufacturing facility, source of whole blood, isolation process among others can restrain the growth of the market. Such rigorous policies could impact the development and manufacturing time of the product thus impacting the growth of the market in the coming years.

SEGMENTATION

By Product Type Analysis

To know how our report can help streamline your business, Speak to Analyst

Protease Inhibitor Segment to Witness Significant Growth of the Market During the Forecast Duration 

On the basis of product type, the market is categorized into albumin, immunoglobulin (intravenous immunoglobulin, and subcutaneous immunoglobulin), coagulation factors (Factor IX, Factor VIII, prothrombin complex concentrates, fibrinogen concentrates and others), protease inhibitors, others. The highest share is captured by immunoglobulin followed by coagulation factors.

However, due to its efficacy in preventing viral infections, protease inhibitors are projected to witness the highest growth in the coming years. Protease inhibitors are widely used as antiviral agents. Increasing outbreaks and incidences of viral outbreaks are estimated to propel the segment growth over the forecast duration. The increasing demand of coagulation factors is driving the growth of the product type.

By Application Analysis

Immunology and Neurology to Witness Highest CAGR

Based on the application, the market for Plasma Fractionation is segmented into immunology & neurology, hematology, critical care pulmonary, and others. The immunology and neurology segments are projected to grow at a higher growth rate over the forecast duration. This is attributed to the extensive use of plasma proteins such as coagulation factors and immunoglobulin in neurology R&D and treatment procedures. Additionally, immunoglobulin has shown promise in treating complex disease indications such as myasthenia gravis, Alzheimer’s among others. Combined with this, there are numerous plasma-based proteins under development and clinical trials for neurology and immunology applications.

The prevalence of genetic disorders such as hemophilia is predicted to fuel the demand for coagulation factors in the coming years. The hematology segment has captured a considerable plasma fractionation market share in 2019.

By End-user Analysis

Hospitals to Register a Higher CAGR over the Forecast Duration

In terms of end-user, the market is categorized into hospitals &clinics, research laboratories, and others (academic institutes). The dominant revenue is generated by the hospitals & clinics segment based on plasma fractionation market trends. This is attributed to the high need for plasma products in advanced clinical settings to treat complex diseases. In addition to this, the rising number of in-patients would boost the market growth.

REGIONAL INSIGHTS

To get more information on the regional analysis of this market, Request a Free sample

The market size in North America stood at USD 10.63 billion in 2019 and is estimated to maintain its dominant position throughout the forecast duration. The dominance of this region is attributable to the increasing number of research and development in the field combined with highly developed infrastructure. Favorable government regulations and recent FDA approvals are projected to further augment the growth of the market in the coming years. In light of the COVID-19 pandemic, the U.S FDA has encouraged the survivors of the disease to actively participate in plasma donations. Europe on the other hand secured the second position in terms of market share. This factor will strongly bolster market growth. Rising prevalence of the rare disease and increasing investments in fractionation systems are augmenting the market growth in the region.

High investment in drug discovery and evolving healthcare research infrastructure in countries like India and China are expected to drive the growth of the market in Asia Pacific. Latin America and the Middle East and Africa are estimated to register comparatively slower growth during the forecast period.

KEY INDUSTRY PLAYERS

Market is Dominated by CSL and Grifols, S.A

The market is consolidated with key players such as CSL and Grifols, S.A. among others dominating the market. Higher spending in research and increased focus on manufacturing biologics are major factors that have led CSL to dominate the market. Grifols and CSL together hold around 45% in terms of global market revenue.

LIST OF KEY COMPANIES PROFILED:

• CSL


• Grifols, S.A


• Baxter


• Kedrion S.p.A


• Octapharma


• Shire


• Biotest AG


• LFB


• Other Prominent Players

KEY INDUSTRY DEVELOPMENTS:

• June 2017 – CSL acquired Wuhan Zhong Yan Rui De Biological Products, one of the key Chinese players in the plasma fractionation market. CSL aims to strengthen its position in the Chinese market.


• October 2018 – Shire announced the completion and commencement of plasma fractionation facility in Georgia, U.S


• October 2018 – Biopharma, a Ukrainian pharmaceutical producer opened an innovative fractionator Bila Tsekva


• March 2020 – One of the hospitals in Huston, U.S was one of the first healthcare institutes to test plasma therapy in a COVID-19. The treatment method is called convalescent serum therapy.

REPORT COVERAGE

An Infographic Representation of Plasma Fractionation Market

View Full Infographic

To get information on various segments, share your queries with us

The market research report provides a detailed analysis of the market and focuses on key aspects such as leading companies, product types, and leading applications of the product. Besides this, the report offers insights into the market trends, highlights key industry developments, and the impact of COVID-19. In addition to the aforementioned factors, the report encompasses several factors that have contributed to the growth of the advanced market over recent years.

To gain extensive insights into the market, Request for Customization

Report Scope & Segmentation